Cargando…

Hepatitis C virus micro-elimination: Where do we stand?

Hepatitis C virus (HCV) elimination by 2030, using direct-acting antiviral treatments, has been promoted by the World Health Organization. This achievement is not attainable, however, particularly after the 2020 pandemic of the coronavirus disease 2019. Consequently, the more realistic objective of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mangia, Alessandra, Cotugno, Rosa, Cocomazzi, Giovanna, Squillante, Maria Maddalena, Piazzolla, Valeria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Minireviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072193/ https://www.ncbi.nlm.nih.gov/pubmed/33967553 http://dx.doi.org/10.3748/wjg.v27.i16.1728

Ejemplares similares

Liver transplantation for hepatocellular carcinoma: Where do we stand?
por: Santopaolo, Francesco, et al.
Publicado: (2019)

Viscoelastic tests in liver disease: where do we stand now?
por: Buliarca, Alina, et al.
Publicado: (2021)

Role of endoscopic ultrasound in liver disease: Where do we stand in 2017?
por: Saraireh, Hamzeh A, et al.
Publicado: (2017)

Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)
por: Mangia, Alessandra, et al.
Publicado: (2022)

Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?
por: Galanopoulos, Michail, et al.
Publicado: (2018)

Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?
por: Mikolasevic, Ivana, et al.
Publicado: (2021)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
por: Cocomazzi, Giovanna, et al.
Publicado: (2021)

Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study
por: Mangia, Alessandra, et al.
Publicado: (2022)

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response
por: Giambra, Vincenzo, et al.
Publicado: (2022)

Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient‐centered program from Italy
por: Mangia, Alessandra, et al.
Publicado: (2021)

Defining the Pseudomonas Genus: Where Do We Draw the Line with Azotobacter?
por: Özen, Asli I., et al.
Publicado: (2011)

437 A TAILORED PROGRAM FOR SCREENING, IMPROVED ACCESS TO CARE, AND PRIORITIZATION OF TREATMENT FOR PWUD WITH CHRONIC HCV INFECTION.
por: Mangia, Alessandra, et al.
Publicado: (2021)

HDV RNA Levels and Progression of Hepatitis Delta Infection: A 14 Year Follow Up Experience in Italy
por: Mangia, Alessandra, et al.
Publicado: (2023)

Where Do We Stand?
Publicado: (1891)

Angiogenesis inhibitors in clinical development; where are we now and where are we going?
por: Eskens, F A L M
Publicado: (2004)

Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?
por: Mangia, Alessandra, et al.
Publicado: (2020)

Eliminating Human African Trypanosomiasis: Where Do We Stand and What Comes Next>
por: Simarro, Pere P, et al.
Publicado: (2008)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Endoscopic therapy for Barrett’s esophagus and early esophageal cancer: Where do we go from here?
por: Singh, Tavankit, et al.
Publicado: (2018)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Where does chemotherapy stands in the treatment of ampullary carcinoma? A review of literature
por: Ghosn, Marwan, et al.
Publicado: (2016)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand?
por: Russo, Francesco Paolo, et al.
Publicado: (2022)

Sessile serrated adenoma/polyps: Where are we at in 2016?
por: Singh, Rajvinder, et al.
Publicado: (2016)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

Pixel Detectors ... where do we stand?
por: Wermes, Norbert
Publicado: (2019)

Laser accelerators : where do we stand
por: Lawson, J D
Publicado: (1985)

Renormalization schemes: where do we stand?
por: Ward, B F L
Publicado: (1990)

Barrett's Esophagus: Where Do We Stand?
por: Al Madi, Majid A.
Publicado: (2009)

Maximizing neuroprotection: where do we stand?
por: Kuffler, Damien P
Publicado: (2012)

LHC Access - Where do we Stand
por: Ninin, P, et al.
Publicado: (2006)

Where do we stand with IPF treatment?
por: Albera, C, et al.
Publicado: (2013)

Genetics of Keratoconus: Where Do We Stand?
por: Abu-Amero, Khaled K., et al.
Publicado: (2014)

Cricoid pressure: Where do we stand?
por: Bhatia, Nidhi, et al.
Publicado: (2014)

Combating Malaria: Where do We Stand?
por: Coats, Mamie T
Publicado: (2016)

Where Do We Stand in Preventive Medicine?
por: Robertson, Wm.
Publicado: (1921)

Bevacizumab in Glaucoma: Where do We Stand?
por: Khanna, Anjani
Publicado: (2012)

Schistosomiasis vaccines: where do we stand?
por: Tebeje, Biniam Mathewos, et al.
Publicado: (2016)

Dupuytren’s disease: where do we stand?
por: Grazina, Rita, et al.
Publicado: (2019)

Telemedicine in India: Where do we stand?
por: Chellaiyan, Vinoth G., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0vl38nmjqv64fopkspsv2q33ba